Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights

NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) will host a teleconference at 8:00 a.m. EDT (7:00 a.m. CDT) on Monday, June 6, 2011, to review data presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Company executives will provide an overview of data presented at the meeting on the oncology portfolio and address inquiries from investors and analysts.

Investors and the general public are invited to listen to a live webcast of the call at: http://investor.bms.com or by dialing 913-312-0677, confirmation code: 2538916. A replay of the call will be available beginning at 11:00 a.m. EDT on June 6 through midnight EDT on June 20. The replay can be accessed at http://investor.bms.com or by dialing 402-280-9013, confirmation code: 2538916.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.



CONTACT:

Bristol-Myers Squibb Company
Media:
Jennifer Fron Mauer, 609-252-6579
[email protected]
or
Investors:
John Elicker, 609-252-4611
[email protected]

KEYWORDS:   United States  North America  Illinois  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Oncology  Other Health

MEDIA:

Logo
 Logo

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.